123 related articles for article (PubMed ID: 8328981)
1. Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells.
Kelley EE; Modest EJ; Burns CP
Biochem Pharmacol; 1993 Jun; 45(12):2435-9. PubMed ID: 8328981
[TBL] [Abstract][Full Text] [Related]
2. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Small GW; Strum JC; Daniel LW
Lipids; 1997 Jul; 32(7):715-23. PubMed ID: 9252959
[TBL] [Abstract][Full Text] [Related]
3. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
4. Membrane lipid modification and sensitivity of leukemic cells to the thioether lipid analogue BM 41.440.
Petersen ES; Kelley EE; Modest EJ; Burns CP
Cancer Res; 1992 Nov; 52(22):6263-9. PubMed ID: 1423272
[TBL] [Abstract][Full Text] [Related]
5. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Chabot MC; Wykle RL; Modest EJ; Daniel LW
Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333
[TBL] [Abstract][Full Text] [Related]
6. Increased generation of lipid-derived and ascorbate free radicals by L1210 cells exposed to the ether lipid edelfosine.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1993 Feb; 53(4):711-3. PubMed ID: 8428351
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
8. Surface-active properties of the antitumour ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (edelfosine).
Busto JV; Sot J; Goñi FM; Mollinedo F; Alonso A
Biochim Biophys Acta; 2007 Jul; 1768(7):1855-60. PubMed ID: 17543274
[TBL] [Abstract][Full Text] [Related]
9. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L).
Mollinedo F; Fernández-Luna JL; Gajate C; Martín-Martín B; Benito A; Martínez-Dalmau R; Modolell M
Cancer Res; 1997 Apr; 57(7):1320-8. PubMed ID: 9102220
[TBL] [Abstract][Full Text] [Related]
10. Membrane transport of mitoxantrone by L1210 leukemia cells.
Burns CP; Haugstad BN; North JA
Biochem Pharmacol; 1987 Mar; 36(6):857-60. PubMed ID: 3566786
[TBL] [Abstract][Full Text] [Related]
11. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
Mollinedo F; de la Iglesia-Vicente J; Gajate C; Estella-Hermoso de Mendoza A; Villa-Pulgarin JA; de Frias M; Roué G; Gil J; Colomer D; Campanero MA; Blanco-Prieto MJ
Clin Cancer Res; 2010 Apr; 16(7):2046-54. PubMed ID: 20233887
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and growth inhibitory properties of glycosides of 1-O-hexadecyl-2-O-methyl-sn-glycerol, analogs of the antitumor ether lipid ET-18-OCH3 (edelfosine).
Marino-Albernas JR; Bittman R; Peters A; Mayhew E
J Med Chem; 1996 Aug; 39(17):3241-7. PubMed ID: 8765506
[TBL] [Abstract][Full Text] [Related]
13. ET-18-OCH3 (edelfosine): a selective antitumour lipid targeting apoptosis through intracellular activation of Fas/CD95 death receptor.
Mollinedo F; Gajate C; Martín-Santamaría S; Gago F
Curr Med Chem; 2004 Dec; 11(24):3163-84. PubMed ID: 15579006
[TBL] [Abstract][Full Text] [Related]
14. Relationship of cell survival, drug dose, and drug uptake after 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine treatment.
Fujiwara K; Daniel LW; Modest EJ; Wallen CA
Cancer Chemother Pharmacol; 1994; 34(6):472-6. PubMed ID: 7923557
[TBL] [Abstract][Full Text] [Related]
15. Edelfosine is incorporated into rafts and alters their organization.
Ausili A; Torrecillas A; Aranda FJ; Mollinedo F; Gajate C; Corbalán-García S; de Godos A; Gómez-Fernández JC
J Phys Chem B; 2008 Sep; 112(37):11643-54. PubMed ID: 18712919
[TBL] [Abstract][Full Text] [Related]
16. Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria.
Mollinedo F; Fernández M; Hornillos V; Delgado J; Amat-Guerri F; Acuña AU; Nieto-Miguel T; Villa-Pulgarín JA; González-García C; Ceña V; Gajate C
Cell Death Dis; 2011 May; 2(5):e158. PubMed ID: 21593790
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of the effect of the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-glycero-3-phosphocholine and some homologous compounds on PKC alpha and PKC epsilon.
Conesa-Zamora P; Mollinedo F; Corbalán-García S; Gómez-Fernández JC
Biochim Biophys Acta; 2005 Feb; 1687(1-3):110-9. PubMed ID: 15708359
[TBL] [Abstract][Full Text] [Related]
19. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
Bazill GW; Dexter TM
Cancer Res; 1990 Dec; 50(23):7505-12. PubMed ID: 2253199
[TBL] [Abstract][Full Text] [Related]
20. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system.
Cabaner C; Gajate C; Macho A; Muñoz E; Modolell M; Mollinedo F
Br J Pharmacol; 1999 Jun; 127(4):813-25. PubMed ID: 10433487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
